Drugs / EX039
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05413655 | Aug 2022 → Dec 2026 expected | Alzheimer disease | Excelsior | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EX039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05413655 ↗ |
| Route | Oral | “The dosage form of EX039 is the capsule for oral use” NCT05413655 ↗ |